BTL Industries v. C-Luxe SPA: Permanent Injunction Secured in Body Sculpting Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | BTL Industries Inc. v. C-Luxe SPA and Casey Hawkins |
| Case Number | 2:23-cv-01453 |
| Court | U.S. District Court for the Northern District of Alabama |
| Duration | Oct 2023 – July 2024 249 days (~8 months) |
| Outcome | Plaintiff Win — Permanent Injunction & Confidential Damages |
| Patents at Issue | |
| Accused Products | Knockoff magnetic body sculpting devices |
Case Overview
The Parties
⚖️ Plaintiff
Global medical technology company and the developer of the EMSCULPT platform, utilizing HIFEM technology. Holds a significant intellectual property portfolio.
🛡️ Defendant
Alabama-based aesthetic services provider. Casey Hawkins is named as an individual co-defendant, a strategic move to ensure injunctive compliance.
The Patent at Issue
This landmark case involved U.S. Patent No. US10478634B2, covering BTL’s proprietary High-Intensity Focused Electromagnetic (HIFEM) body sculpting technology — commercialized under the globally recognized EMSCULPT and EMSCULPT NEO brands. HIFEM technology represents a defensible, clinically differentiated innovation in non-surgical body contouring, making BTL’s patent portfolio a high-value enforcement asset.
- • US10478634B2 — High-Intensity Focused Electromagnetic (HIFEM) body sculpting technology
Developing an aesthetic device?
Verify your product’s freedom to operate against medical device patents before launch.
The Verdict & Legal Analysis
Outcome
The court entered a Consent Judgment and Permanent Injunction in favor of BTL Industries, representing a judgment on the merits for the plaintiff. All claims were dismissed with prejudice. The defendants allegedly used unauthorized devices and deployed BTL’s protected trademarks to market competing services, exposing a broader industry problem: the proliferation of imitation aesthetic devices misrepresenting association with established brands.
Key Legal Issues
The verdict cause is classified as an Infringement Action, encompassing both patent infringement under 35 U.S.C. § 271 and trademark infringement under the Lanham Act. The breadth of the injunction’s prohibitions — covering use, importation, sale, promotion, and even third-party encouragement — indicates BTL pursued and secured comprehensive relief well beyond mere cessation of infringing activity. The inclusion of Casey Hawkins as an individual defendant alongside C-Luxe SPA is a deliberate enforcement tactic to ensure long-term compliance monitoring.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in medical device design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this medical device litigation.
- View all related patents in HIFEM technology space
- See which companies are most active in body sculpting IP
- Understand claim construction for HIFEM devices
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your medical aesthetic device.
- Input your device description or technical specs
- AI identifies potentially blocking medical device patents
- Get actionable risk assessment report
High Risk Area
HIFEM-adjacent body sculpting devices
US10478634B2 Family
In medical aesthetic technology space
Design-Around Options
Feasible with expert IP counsel
✅ Key Takeaways
Consent judgments with permanent injunctions can deliver comprehensive relief equivalent to trial victories — with greater speed and cost efficiency.
Search related case law →Dual patent/trademark pleading strategies maximize injunctive scope in technology-branded product cases.
Explore precedents →Individual defendant naming in service-business infringement cases is a durable enforcement mechanism.
View enforcement strategies →Frequently Asked Questions
The case involved U.S. Patent No. US10478634B2, covering BTL’s High-Intensity Focused Electromagnetic (HIFEM) body sculpting technology, commercialized as EMSCULPT and EMSCULPT NEO.
The Northern District of Alabama entered a Consent Judgment and Permanent Injunction in favor of BTL Industries on July 1, 2024, with confidential damages and a comprehensive prohibition on defendants’ infringing activities.
This case reinforces aggressive dual patent/trademark enforcement strategies against downstream service providers, signaling elevated litigation risk for aesthetics businesses deploying unauthorized HIFEM-equivalent devices.
Companies developing medical aesthetic devices should conduct thorough Freedom-to-Operate (FTO) analysis, ensure robust trademark clearance for product names, and engage IP counsel early in the development and marketing process. PatSnap Eureka’s tools assist in identifying blocking patents and assessing infringement risk.
Ready to Secure Your Medical Device Innovations?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the Northern District of Alabama — Case 2:23-cv-01453
- USPTO Patent Full-Text Database — US10478634B2
- Cornell Legal Information Institute — 35 U.S.C. § 271 (Patent Infringement)
- Cornell Legal Information Institute — Lanham Act (Trademark Act)
- PatSnap — IP Intelligence Solutions for Medical Technology
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.